Literature DB >> 34380055

Feasibility and Outcomes of Renal Mass Biopsy for Anatomically Complex Renal Tumors.

Selma Masic1, Marshall Strother1, Laura C Kidd1, Brian Egleston2, Avery Braun1, Abhishek Srivastava1, Marc Smaldone1, Barton Milestone3, Rosaleen Parsons3, Rosalia Viterbo1, Richard Greenberg1, David Chen1, Alexander Kutikov1, Robert Uzzo4.   

Abstract

OBJECTIVE: To compare the feasibility and outcomes of renal mass biopsies (RMB) of anatomically complex vs non-complex renal masses.
METHODS: Our institutional renal tumor database was queried for patients who underwent RMB between 2005 and 2019 and with available nephrometry score. Complex masses were: (1) small (<2 cm), (2) entirely endophytic (nephrometry E=3), (3) hilar (h) or (4) partially endophytic (E=2) and anterior. Demographic and pathologic data were compared. Biopsies were deemed adequate if they resulted in a diagnosis. Concordance with surgical pathology was assessed. These were both presented using proportions. Factors associated with biopsy outcomes were identified using multivariable logistic regression. RMB sensitivity and specificity were calculated using contingency methods.
RESULTS: A total of 306 RBMs were included, 179 complex and 127 non-complex. A total of 199 (65%) had an extirpative procedure. Complex lesions were less likely to have an adequate biopsy (89% vs 96%, P = .03), and to be concordant with final surgical pathology from an oncologic standpoint (89% vs 97%, P = .03). There was no significant difference in concordance of histology (76% vs 86%, P = .10) or grade (48 vs 51%, P = .66). On multivariable analyses, only male gender was associated with biopsy adequacy (OR 3.31, 95% CI 1.28-8.55, P = .01). Our overall sensitivity was 93%, specificity 93%, and accuracy 93%. There were no significant differences over time in biopsy outcomes during the study period.
CONCLUSION: RMB of complex lesions is associated with excellent diagnostic yield, albeit lower than non-complex lesions. RMB should not be deferred in cases of anatomically complex lesions where additional data could improve clinical decision-making.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34380055      PMCID: PMC9039834          DOI: 10.1016/j.urology.2021.07.026

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.633


  23 in total

1.  The penetration of renal mass biopsy in daily practice: a survey among urologists.

Authors:  Kurdo Barwari; Jean J de la Rosette; M Pilar Laguna
Journal:  J Endourol       Date:  2012-02-10       Impact factor: 2.942

2.  Can renal mass biopsy assessment of tumor grade be safely substituted for by a predictive model?

Authors:  Claudio Jeldres; Maxine Sun; Daniel Liberman; Giovanni Lughezzani; Alexandre de la Taille; Jacques Tostain; Antoine Valeri; Luca Cindolo; Vincenzo Ficarra; Walter Artibani; Richard Zigeuner; Arnaud Mejean; Jean Luc Descotes; Eric Lechevallier; Peter F Mulders; Paul Perrotte; Jean-Jacques Patard; Pierre I Karakiewicz
Journal:  J Urol       Date:  2009-12       Impact factor: 7.450

3.  Pretreatment Diagnosis of the Small Renal Mass: Status of Renal Biopsy in the United States of America.

Authors:  Roshan M Patel; Shoaib Safiullah; Zhamshid Okhunov; Daniel Meller; Kathryn Osann; Kamaljot Kaler; Jaime Landman; Ralph V Clayman
Journal:  J Endourol       Date:  2018-08-10       Impact factor: 2.942

4.  Ultrasound-guided core biopsy of small renal masses: diagnostic rate and limitations.

Authors:  Sung Yoon Park; Byung Kwan Park; Chan Kyo Kim; Ghee Young Kwon
Journal:  J Vasc Interv Radiol       Date:  2012-12-01       Impact factor: 3.464

5.  Image-guided biopsy of small (≤4 cm) renal masses: the effect of size and anatomical location on biopsy success rate and complications.

Authors:  Matthew J Seager; Uday Patel; Christopher J Anderson; Michael Gonsalves
Journal:  Br J Radiol       Date:  2018-02-22       Impact factor: 3.039

6.  The evolving presentation of renal carcinoma in the United States: trends from the Surveillance, Epidemiology, and End Results program.

Authors:  Mike M Nguyen; Inderbir S Gill; Lars M Ellison
Journal:  J Urol       Date:  2006-12       Impact factor: 7.450

7.  Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram.

Authors:  Alexander Kutikov; Brian L Egleston; Yu-Ning Wong; Robert G Uzzo
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

8.  The natural history of incidentally detected small renal masses.

Authors:  Alessandro Volpe; Tony Panzarella; Ricardo A Rendon; Masoom A Haider; Filippos I Kondylis; Michael A S Jewett
Journal:  Cancer       Date:  2004-02-15       Impact factor: 6.860

Review 9.  Active Surveillance for Small Renal Masses: When Less is More.

Authors:  Benjamin T Ristau; Alexander Kutikov; Robert G Uzzo; Marc C Smaldone
Journal:  Eur Urol Focus       Date:  2017-04-19

10.  Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival.

Authors:  Ahmedin Jemal; Elizabeth M Ward; Christopher J Johnson; Kathleen A Cronin; Jiemin Ma; Blythe Ryerson; Angela Mariotto; Andrew J Lake; Reda Wilson; Recinda L Sherman; Robert N Anderson; S Jane Henley; Betsy A Kohler; Lynne Penberthy; Eric J Feuer; Hannah K Weir
Journal:  J Natl Cancer Inst       Date:  2017-09-01       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.